DOCSLIB.ORG

Mckesson CORPORATION (Exact Name of Registrant As Specified in Its Charter)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mckesson CORPORATION (Exact Name of Registrant As Specified in Its Charter) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-13252 McKESSON CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3207296 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 6555 State Hwy 161, Irving, TX 75039 (Address of principal executive offices, including zip code) (972) 446-4800 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: (Title of each class) (Trading Symbol) (Name of each exchange on which registered) Common stock, $0.01 par value MCK New York Stock Exchange 0.625% Notes due 2021 MCK21A New York Stock Exchange 1.500% Notes due 2025 MCK25 New York Stock Exchange 1.625% Notes due 2026 MCK26 New York Stock Exchange 3.125% Notes due 2029 MCK29 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant’s most recently completed second fiscal quarter, September 30, 2019, was approximately $25 billion. Number of shares of common stock outstanding on April 30, 2020: 161,853,218 DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Proxy Statement for its 2020 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Table of Contents McKESSON CORPORATION TABLE OF CONTENTS Item Page PART I 1. Business 3 1A. Risk Factors 10 1B. Unresolved Staff Comments 19 2. Properties 19 3. Legal Proceedings 19 4. Mine Safety Disclosures 19 Executive Officers of the Registrant 20 PART II 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 21 6. Selected Financial Data 23 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 25 7A. Quantitative and Qualitative Disclosures About Market Risk 49 8. Financial Statements and Supplementary Data 50 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 126 9A. Controls and Procedures 126 9B. Other Information 126 PART III 10. Directors, Executive Officers and Corporate Governance 127 11. Executive Compensation 127 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 127 13. Certain Relationships and Related Transactions and Director Independence 129 14. Principal Accounting Fees and Services 129 PART IV 15. Exhibits and Financial Statement Schedule 130 16. Form 10-K Summary 130 Signatures 136 Table of Contents McKESSON CORPORATION PART I Item 1. Business. General McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns), originally founded in 1833, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with life sciences companies, manufacturers, providers, pharmacies, governments and other healthcare organizations to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references in this document to a particular year shall mean the Company’s fiscal year. The Company was incorporated on July 7, 1994 in the State of Delaware. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act,”) are available free of charge on the Company’s website (www.mckesson.com under the “Investors — Financials — SEC Filings” caption) as soon as reasonably practicable after such material is electronically filed with, or furnished to, the Securities and Exchange Commission (“SEC” or the “Commission”). The content on any website referred to in this Annual Report on Form 10-K is not incorporated by reference into this report, unless expressly noted otherwise. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC. The address of the website is www.sec.gov. Business Segments The Company operates its business through three reportable segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions and Medical-Surgical Solutions. All remaining operating segments and business activities that are not significant enough to require separate reportable segment disclosure are referred to and included in Other. Our U.S. Pharmaceutical and Specialty Solutions segment distributes branded, generic, specialty, biosimilar and over-the-counter (“OTC”) pharmaceutical drugs and other healthcare-related products. This segment provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. This segment also provides solutions for life sciences companies including offering multiple distribution channels and clinical trial access to specific patient populations through our network of oncology physicians. In addition, the segment sells financial, operational and clinical solutions to pharmacies (retail, hospital, alternate site) and provides consulting, outsourcing and other services. Our European Pharmaceutical Solutions segment provides distribution and services to wholesale, institutional and retail customers in 13 European countries where we own, partner or franchise with retail pharmacies, as further described below. Our Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers in the United States. Other primarily consists of the following: • McKesson Canada which provides better, safer care by delivering vital medicines, supplies and information technologies throughout Canada and operates Rexall Health retail pharmacies; • McKesson Prescription Technology Solutions (“MRxTS”) which provides innovative technological and connectivity solutions to pharmaceutical companies, retail pharmacies, health systems, clinics and payers across the healthcare industry; and • Our investment in the Change Healthcare joint venture, which was separated from the Company in the fourth quarter of 2020 as discussed in more detail below. 3 Table of Contents McKESSON CORPORATION U.S. Pharmaceutical and Specialty Solutions Segment: Our U.S. Pharmaceutical and Specialty Solutions segment provides distribution and logistics services for branded, generic, specialty, biosimilar and OTC pharmaceutical drugs along with other healthcare-related products to customers. This business provides solutions and services to pharmacies, hospitals, pharmaceutical manufacturers, physicians, payers and patients throughout the United States
Load more

Recommended publications
  • HEALTH BENEFITS Providing Value for Our Employees
    HEALTH BENEFITS Providing Value for Our Employees March 2017 Business Roundtable CEO members lead companies with more than $6 trillion in annual revenues and nearly 15 million employees. The combined market capitalization of Business Roundtable member companies is the equivalent of nearly one-quarter of total U.S. stock market capitalization, and Business Roundtable members invest $103 billion annually in research and development — equal to 30 percent of U.S. private R&D spending. Our companies pay $226 billion in dividends to shareholders and generate $412 billion in revenues for small and medium-sized businesses annually. Business Roundtable companies also make more than $7 billion a year in charitable contributions. Please visit us at www.brt.org, check us out on Facebook and LinkedIn, and follow us on Twitter. Copyright © 2017 by Business Roundtable HEALTH BENEFITS Providing Value for Our Employees March 2017 March 2017 DEAR BUSINESS LEADERS AND STAKEHOLDERS: I am pleased to share with you a new report highlighting what leading U.S. companies are doing to improve health outcomes for our employees and their families. America’s employer-sponsored health benefits system is the foundation of health care in the United States. Of the 209 million Americans who are covered by health insurance plans, 85 percent — or 177 million Americans* — receive health coverage through an employer. This report demonstrates many different ways employers are helping to drive a health care system that delivers better health care quality and value. I hope you find this report helpful. Sincerely, Brian Moynihan Chairman and Chief Executive Officer Bank of America * Bureau of Labor Statistics, Health Insurance Coverage in the United States: 2015, Current Population Reports, September 2016.
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • Mckesson CORPORATION
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ‘ Filed by a Party other than the Registrant Check the appropriate box: ‘ Preliminary Proxy Statement ‘ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) Definitive Proxy Statement ‘ Definitive Additional Materials ‘ Soliciting Material Pursuant to §240.14a-12 McKESSON CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. ‘ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ‘ Fee paid previously with preliminary materials. ‘ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: A LETTER FROM OUR INDEPENDENT CHAIR Dear Fellow Shareholders, First and foremost, on behalf of the Board of Directors, I would like to thank you for your investment in McKesson and for the confidence you place in this Board to oversee your interests in our Company particularly through the most unprecedented global health crisis in modern history.
    [Show full text]
  • UCLA-Ledgerdomain-PDG
    UCLA-LeDgerDomain: DSCSA Solution Through Blockchain Technology Drug Tracking, Tracing, anD Verification at the Last Mile of the Pharmaceutical Supply Chain with BRUINchain FDA Submitter: Han-Lian William Chien, PharmD, MBA Chief Pharmacy Officer: Josenor “Jess” DeJesus, PharmD, MBA, FACHE Senior Supervising Dispenser: Jennifer Colon, PharmD Prescriber: Prof. Perry B. Shieh, MD,PhD RonalD Reagan UCLA MeDical Center ThanKing Biogen serialization PDG Member & Presenter: Ben Taylor, CEO, LeDgerDomain team leD by Bjoern Rosner, PhD As well as Imran ShaKur PDG FDA Pilot Program Round Robin, July 2020 1 Partnering Entities. UCLA Health UCLA Health’s five facilities & >200 clinics serve 600,000 unique patients yearly UCLA Health Pharmacy’s 300+ staffers support three hospital pharmacies, an infusion pharmacy, two research pharmacies & five retail/specialty pharmacies UCLA partnered with LedgerDomain to build WORKING APP to apply DSCSA requirements to a large hospital pharmacy: the most complex LAST MILE Please take a moment to thank UCLA’s COVID responders 2 Partnering Entities. LedgerDomain Built KitChain for Clinical Supply FDA Naloxone Challenge Blockchain Working Group fda.gov/NewsEvents/PublicHealthFocus/ucm533711.htm Member, Hyperledger Project 3 Pilot Project Key Objectives. Last Mile DSCSA Objectives Assist colleagues to perform robust DSCSA checks & verification Flag double-counts and surface suspect transactions Enforce ground truth with exception handling; gradually escalate to 3911 Provide real-time inventory & quarantine at the
    [Show full text]
  • Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I
    Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I. Imaging Systems Corp A.L.I. Technologies (International) LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Division Abbott Nutrition Products Division Abbott Pharmaceutical Products Group Abbott Point of Care Division Abbott Vascular Division Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Advanced Neuromodulation Systems, Inc. Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Aesculap Implant Systems, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Alaven Pharmaceuticals, LLC 2260 Northwest parkway Suite A Marietta GA 30067 Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allen Medical Systems, Inc. Allergan Sales, LLC Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Alpharma Pharmaceuticals, Inc. Alpharma Pharmaceuticals, LLC AMAG Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421 AMATECH Corporation American Medical Distributors, Inc. 100 New Highway N Amityville NY 11701 American Medical System,
    [Show full text]
  • Rebateable Manufacturers
    Rebateable Labelers – July 2021 Manufacturers are responsible for updating their eligible drugs and pricing with CMS. Montana Healthcare Programs will not pay for an NDC not updated with CMS. Note: Some manufacturers on this list may have some NDCs that are covered and others that are not. Manufacturer ID Manufacturer Name 00002 ELI LILLY AND COMPANY 00003 E.R. SQUIBB & SONS, LLC. 00004 HOFFMANN-LA ROCHE 00006 MERCK & CO., INC. 00007 GLAXOSMITHKLINE 00008 WYETH PHARMACEUTICALS LLC, 00009 PHARMACIA AND UPJOHN COMPANY LLC 00013 PFIZER LABORATORIES DIV PFIZER INC 00015 MEAD JOHNSON AND COMPANY 00023 ALLERGAN INC 00024 SANOFI-AVENTIS, US LLC 00025 PFIZER LABORATORIES DIV PFIZER INC 00026 BAYER HEALTHCARE LLC 00032 ABBVIE INC. 00037 MEDA PHARMACEUTICALS, INC. 00039 SANOFI-AVENTIS, US LLC 00046 WYETH PHARMACEUTICALS INC. 00049 ROERIG 00051 ABBVIE INC 00052 ORGANON USA INC. 00053 CSL BEHRING L.L.C. 00054 HIKMA PHARMACEUTICAL USA, INC. 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00065 ALCON LABORATORIES, INC. 00068 AVENTIS PHARMACEUTICALS 00069 PFIZER LABORATORIES DIV PFIZER INC 00071 PARKE-DAVIS DIV OF PFIZER 00074 ABBVIE INC 00075 AVENTIS PHARMACEUTICALS, INC. 00078 NOVARTIS 00085 SCHERING CORPORATION 00087 BRISTOL-MYERS SQUIBB COMPANY 00088 AVENTIS PHARMACEUTICALS 00093 TEVA PHARMACEUTICALS USA, INC. 00095 BAUSCH HEALTH US, LLC Page 1 of 19 Manufacturer ID Manufacturer Name 00096 PERSON & COVEY, INC. 00113 L. PERRIGO COMPANY 00115 IMPAX GENERICS 00116 XTTRIUM LABORATORIES, INC. 00121 PHARMACEUTICAL ASSOCIATES, INC. 00131 UCB, INC. 00132 C B FLEET COMPANY INC 00143 HIKMA PHARMACEUTICAL USA, INC. 00145 STIEFEL LABORATORIES, INC, 00168 E FOUGERA AND CO. 00169 NOVO NORDISK, INC. 00172 TEVA PHARMACEUTICALS USA, INC 00173 GLAXOSMITHKLINE 00178 MISSION PHARMACAL COMPANY 00185 EON LABS, INC.
    [Show full text]
  • Grossman V. Johnson & Johnson Et Al. Complaint
    Case3:14-cv-03557 Document1 Filed08/06/14 Page1 of 27 1 THOMAS SIMS (SBN 264174) [email protected] 2 RUSSELL BUDD [email protected] 3 BARON & BUDD, P. C. 3102 Oak Lawn Ave, Suite 1100 4 Dallas, Texas 75219 Telephone: (214) 521-3605 5 Facsimile: (214) 520-1181 6 Attorneys for Plaintiff 7 UNITED STATES DISTRICT COURT 8 NORTHERN DISTRICT OF CALIFORNIA 9 SAN FRANCISCO DIVISION 10 KARYN JOY GROSSMAN; 11 Case No.: _______________3:14-cv-03557 12 Plaintiff, v. 13 COMPLAINT FOR DAMAGES JOHNSON & JOHNSON; JOHNSON & JOHNSON AND 14 PHARMACEUTICAL RESEARCH & DEMAND FOR JURY TRIAL DEVELOPMENT, L.L.C.; ORTHO-MCNEIL- 15 JANSSEN PHARMACEUTICALS, INC.; and 1. Strict Liability 2. Product Liability - Failure to 16 MCKESSON CORPORATION; Warn 17 Defendants. 3. Negligence 4. Breach of Express Warranty 18 5. Breach of Implied Warranty 6. Fraud 19 7. Negligent Representation 8. Fraudulent Concealment 20 21 22 Plaintiff, by and through the undersigned counsel, hereby brings this Complaint for 23 damages against the Defendants, and alleges the following: 24 INTRODUCTION 25 1. This is an action for damages suffered by Plaintiff as a direct and proximate 26 result of Defendants’ negligent and wrongful conduct in connection with the design, 27 development, manufacture, testing, packaging, promoting, marketing, advertising, distribution, 28 1 COMPLAINT Case3:14-cv-03557 Document1 Filed08/06/14 Page2 of 27 1 labeling, and/or sale of the pharmaceutical drug Levaquin® (also known as levofloxacin). 2 Levaquin® in any of its forms shall herein be referred to as “Levaquin.” Plaintiff maintains that 3 Levaquin is defective, dangerous to human health, unfit and unsuitable to be marketed and sold 4 in commerce, and lacked proper warnings and directions as to the dangers associated with its 5 use.
    [Show full text]
  • COVID-19 Vaccine: Product Information Guide Summary
    COVID-19 Vaccine Product Information Guide Vaccination Card Product Information Guide for COVID-19 Vaccines and Associated Products July 26, 2021 CS321629-V 1 COVID-19 Vaccine Product Information Guide Contents Purpose & How To Use This Guide . 3 Centrally Distributed Vaccines and Ancillary Kits: Moderna . 4 Centrally Distributed Vaccines and Ancillary Kits: Janssen . 6 Ancillary Supply Administration Kit: Standard Syringe (Centrally Distributed) . 7 Centrally Distributed Ancillary Supply Kit Volume . 9 Direct-Ship Vaccine and Ancillary Kit: Pfizer-BioNTech . 10 Combined Administration and Mixing Kit-450 (Direct Ship) Pfizer-BioNTech . 12 Large Combined Ancillary Supply Kit for Administration and Mixing (Direct Ship) Pfizer-BioNTech . 14 Dry Ice Kit (Direct Ship) . 16 Contents and Quantities for Mega Kits to Support Pfizer-BioNTech Vaccine . 17 Addendum: COVID-19 Vaccine Ancillary Supply Kit Guidance . 18 Possible Ancillary Kits—COVID-19 Vaccines Supporting 100 Doses (Moderna and Janssen) . 21 Possible Ancillary Kits—COVID-19 Vaccines Supporting 140 Doses (Moderna) . 22 Possible Ancillary Kits—COVID-19 Vaccine Supporting 450 Doses (Pfizer-BioNTech) . 23 Possible Ancillary Kits—COVID-19 Vaccine Supporting 1,170 Doses (Pfizer-BioNTech) . 24 General Needle and Syringe Resources . 25 Specific Ancillary Kit Products and Product Information . 26 Gold Coast CarePoint Safety Needles and Syringes . 31 Gold Coast Easy Touch FlipLock Safety Syringes Brochure . 32 Gold Coast Easy Touch FlipLock Safety Syringes Brochure . 33 Gold Coast Easy Touch Fluringe Fliplock Safety Syringes . 34 HTL Strefa DropSafe Syringe with Safety Needle Instructions for Use . 35 Retractable Technologies Inc VanishPoint® Syringe Flyer . 36 Smiths Medical Needle-Pro® and Needle-Pro® Edge™ Safety Devices . 37 Pfizer-BioNTech COVID-19 Vaccine and Low Dead-Volume (LDV) Syringes and/or Needles .
    [Show full text]
  • Product Information Guide for COVID-19 Vaccines and Associated Products
    Product Information Guide for COVID-19 Vaccines and Associated Products Version 5–February 13, 2021 Contents Product Information Guide Summary ........................................................................................................................2 Centrally Distributed Vaccines and Ancillary Kits .......................................................................................................3 Vaccines (Centrally Distributed) .............................................................................................................................................. 3 Ancillary Supply Administration Kit: Standard Syringe (Centrally Distributed) ....................................................................... 4 Centrally Distributed Ancillary Supply Kit Volume .................................................................................................................. 5 Direct-Ship Vaccine and Ancillary Kit ..........................................................................................................................6 Pfizer Vaccine (Direct Ship) ..................................................................................................................................................... 6 Large Combined Ancillary Supply Kit for Administration and Mixing (Direct Ship) ................................................................. 7 Combined Ancillary Supply Kit for Administration and Mixing (Direct Ship) .......................................................................... 8 Dry
    [Show full text]
  • Opioid Prescriptions Filled in The
    VIRGINIA: IN THE CIRCUIT COURT FOR WISE COUNTY AND THE CITY OF NORTON CITY OF NORTON, VIRGINIA, Plaintiff, v. PURDUE PHARMA, L.P.; PURDUE PHARMA, INC.; THE PURDUE FREDERICK COMPANY, INC.; RHODES PHARMACEUTICALS, L.P.; ABBOTT LABORATORIES; ABBOTT LABORATORIES, INC.; MALLINCKRODT PLC; MALLINCKRODT LLC; ENDO HEALTH SOLUTIONS, INC; ENDO Case No. CL18 - __________ PHARMACEUTICALS, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; Jury Trial Demanded PAR PHARMACEUTICAL, INC.; TEVA PHARMACEUTICALS USA, INC.; CEPHALON, INC.; BARR LABORATORIES, INC.; JANSSEN PHARMACEUTICALS, INC.; ORTHO- MCNEIL-JANSSEN PHARMACEUTICALS, INC.; JANSSEN PHARMACEUTICA, INC.; WATSON LABORATORIES, INC.; ALLERGAN PLC; ACTAVIS PHARMA, INC.; ACTAVIS, LLC; INSYS THERAPEUTICS, INC.; KVK-TECH, INC.; AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; AMNEAL PHARMACEUTICALS, INC.; AMNEAL PHARMACEUTICALS OF NEW YORK, LLC; MYLAN PHARMACEUTICALS, INC.; MCKESSON CORPORATION; MCKESSON MEDICAL-SURGICAL INC.; CARDINAL HEALTH, INC.; AMERISOURCEBERGEN DRUG CORPORATION; HENRY SCHEIN, INC.; GENERAL INJECTABLES & VACCINES, INC.; INSOURCE, INC.; CVS HEALTH CORPORATION; CVS PHARMACY, INC.; CVS TN DISTRIBUTION, L.L.C.; WALGREENS BOOTS ALLIANCE, INC.; WALGREEN CO.; EXPRESS SCRIPTS HOLDING COMPANY; EXPRESS SCRIPTS, INC; CAREMARK RX, L.L.C.; CAREMARKPCS HEALTH, L.L.C.; CAREMARK, L.L.C.; UNITEDHEALTH GROUP INCORPORATED; OPTUM, INC.; OPTUMRX, INC.; and DOES 1-100, Defendants. ii PLAINTIFF’S ORIGINAL COMPLAINT Plaintiff, the City of Norton, Virginia, by and through the undersigned attorneys, (hereinafter
    [Show full text]
  • Complaint (PDF)
    Case 3:17-cv-02375-JCS Document 1 Filed 04/26/17 Page 1 of 16 1 JEE YOUNG YOU (State Bar No. 241658) Email: [email protected] 2 ARNOLD & PORTER KAYE SCHOLER LLP Three Embarcadero Center, 10th Fl. 3 San Francisco, CA 94111-4024 Telephone: (415) 471-3364 4 Facsimile: (415 ) 471-3400 5 Attorneys for Defendants PFIZER INC. and GREENSTONE LLC. 6 7 UNITED STATES DISTRICT COURT 8 FOR THE NORTHERN DISTRICT OF CALIFORNIA 9 KRYSTYNE LOPEZ, Case No. 17-2375 10 Plaintiff, NOTICE OF REMOVAL BY 11 DEFENDANTS PFIZER INC., AND v. GREENSTONE LLC 12 PFIZER, INC., GREENSTONE LLC, 13 MCKESSON CORPORATION, and DOES 1-50, 14 Defendants. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 NOTICE OF REMOVAL Case 3:17-cv-02375-JCS Document 1 Filed 04/26/17 Page 2 of 16 1 TABLE OF CONTENTS 2 Page 3 I. JURISDICTION .....................................................................................................................1 4 A. There is Complete Diversity of Citizenship Between All Properly Joined Parties...........................................................................................................................1 5 6 B. The Amount-in-Controversy is Satisfied .....................................................................2 7 II. REMOVAL IS PROPER BECAUSE MCKESSON IS FRAUDULENTLY JOINED................................................................................................................................... 4 8 A. There is No Factual Predicate that McKesson Distributed the Drug Plaintiff 9 Allegedly Used.............................................................................................................5
    [Show full text]
  • Manufacturers and Wholesalers Street City ST Zip Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Road, Dept
    2018 AB128 Code of Conduct Compliant Companies report Manufacturers and Wholesalers Street City ST Zip Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accutron Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acell, Inc. 6640 Eli Whitney Drive, Suite 200 Columbia MD 21046 Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne PA 19087 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Adamas Pharmaceuticals, Inc. 1900 Powell St., Suite 750 Emeryville CA 94608 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products Services, Inc. Aegerion Pharmaceuticals, Inc. One Main Street, Suite 800 Cambridge MA 02142 Aerie Pharmaceuticals, Inc. 2030 Main St., Suite 1400 Irvine CA 92614 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS Inc. Akrimax Pharmaceuticals, LLC 11 Commerce Drive, 1st Floor Cranford NJ 07016 Alamo Pharma Services, Inc. Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alden Optical Laboratories, Inc. Aldenex Vision LLC Alimera Sciences, Inc. 6120 Windward Parkway, Suite 290 Alpharetta GA 30005 Alkermes, Inc.
    [Show full text]